At #MAO2025, Dr. Camille Chakiba presented the PRIORITY study on cancer patients’ care goals:
📌 Key finding: Patients 70+ prioritize treatment efficacy, while oncologists emphasize toxicity risks more than patients themselves.
💡 Takeaway: Goals must be discussed case by case!
#Oncogeriatrics

📢 #MAO2025 | Chemo + IO in metastatic NSCLC for ≥65:
🔹 Meta-analysis (Dr. Emeline Orillard)
✅ Improved OS & PFS with IO in ≥65
❗ No significant benefit after 75 (small sample size)
📊 Update ongoing + need for raw data sharing.
#NSCLC #Immunotherapy #GeriatricOncology #MAO2025

🔬 ADC & elderly breast cancer patients 👵🎗️

At #MAO2025, experts highlighted:
✅ Efficacy signal in 65+ but limited data for older patients
⚠️ More toxicity & treatment discontinuation
🚀 Include elderly in innovation but with vigilance

#Oncogeriatrics #BreastCancer #ADC #CancerResearch

📢 Capucine Baldini at MAO 2025:
• ✅ No loss of efficacy of immunotherapy in older patients
• ❓ Immunosenescence impact? Still unclear
• 🔍 Need for prospective clinical & translational data

#MAO2025 #OncoGeriatrics #Immunotherapy